Article Versions Notes

Ashoura NR, Saad HM, El Zahaby EI, Salama AR, Amer NE, Elhussieny O, Edres HA, Nematalla HA, Mohammed SAA. Effect of Nano-Gefitinib on Solid Ehrlich Carcinoma via Targeting EGFR, RIPK2 Pathways, and Macrophage Reprogramming. Pharmaceuticals. 2025; 18(11):1747. https://doi.org/10.3390/ph18111747

Ashoura, Neveen R., Hebatallah M. Saad, Enas I. El Zahaby, Alyaa R. Salama, Nihal E. Amer, Omnya Elhussieny, Hanan A. Edres, Hisham A. Nematalla, and Salman A. A. Mohammed. 2025. "Effect of Nano-Gefitinib on Solid Ehrlich Carcinoma via Targeting EGFR, RIPK2 Pathways, and Macrophage Reprogramming" Pharmaceuticals 18, no. 11: 1747. https://doi.org/10.3390/ph18111747

Ashoura, N. R., Saad, H. M., El Zahaby, E. I., Salama, A. R., Amer, N. E., Elhussieny, O., Edres, H. A., Nematalla, H. A., & Mohammed, S. A. A. (2025). Effect of Nano-Gefitinib on Solid Ehrlich Carcinoma via Targeting EGFR, RIPK2 Pathways, and Macrophage Reprogramming. Pharmaceuticals, 18(11), 1747. https://doi.org/10.3390/ph18111747